|
1
|
Maeda K, Shibutani M, Otani H, Nagahara H,
Ikeya T, Iseki Y, Tanaka H, Muguruma K and Hirakawa K:
Inflammation-based factors and prognosis in patients with
colorectal cancer. World J Gastrointest Oncol. 7:111–117.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hamilton S and Aaltonen L: Tumors of the
colon and rectum. In: World Health Organization Classification of
Tumors. Pathol Genet Tumors Dig Syst IARC Press Lyon pp103-104,
2000.
|
|
3
|
Laird BJ, Kaasa S, McMillan DC, Fallon MT,
Hjermstad MJ, Fayers P and Klepstad P: Prognostic factors in
patients with advanced cancer: A comparison of clinicopathological
factors and the development of an inflammation-based prognostic
system. Clin Cancer Res. 19:5456–5464. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lu H, Ouyang W and Huang C: Inflammation,
a key event in cancer development. Mol Cancer Res. 4:221–233.
2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McMillan DC: The systemic
inflammation-based Glasgow prognostic score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H,
et al: Prognostic significance of the lymphocyte-to-monocyte ratio
in patients with metastatic colorectal cancer. World J
Gastroenterol. 21:9966–9973. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rasic I, Rebic V, Rasic A, Aksamija G and
Radovic S: The association of simultaneous increase in
interleukin-6, C reactive protein, and matrix metalloproteinase-9
serum levels with increasing stages of colorectal cancer. J Oncol.
2018(2830503)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yamamoto M, Saito H, Uejima C, Tanio A,
Takaya S, Sakamoto T, Honjo S, Maeta Y, Ashida K and Fujiwara Y:
Prognostic value of the combination of pre- and postoperative
C-reactive protein in colorectal cancer patients. Surg Today.
48:986–993. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chua W, Charles KA, Baracos VE and Clarke
SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in
patients with advanced colorectal cancer. Br J Cancer.
104:1288–1295. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maeda K, Shibutani M, Otani H, Nagahara H,
Sugano K, Ikeya T, Kubo N, Amano R, Kimura K, Muguruma K, et al:
Low nutritional prognostic index correlates with poor survival in
patients with stage IV colorectal cancer following palliative
resection of the primary tumor. World J Surg. 38:1217–1222.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhou ZQ, Pang S, Yu XC, Xue Q, Jiang HY,
Liang XJ and Liu L: Predictive values of postoperative and dynamic
changes of inflammation indexes in survival of patients with
resected colorectal cancer. Curr Med Sci. 38:798–808.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
He WZ, Hu WM, Kong PF, Yang L, Yang YZ,
Xie QK, Jiang C, Yin CX, Qiu HJ, Zhang B, et al: Systemic
neutrophil lymphocyte ratio and mismatch repair status in
colorectal cancer patients: Correlation and prognostic value. J
Cancer. 9:3093–3100. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 92:205–216. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jakubowska K, Kisielewski W, Kańczuga-Koda
L, Koda M and Famulski W: Diagnostic value of inflammatory cell
infiltrates, tumor stroma percentage and disease-free survival in
patients with colorectal cancer. Oncol Lett. 14:3869–3877.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mayadas TN, Cullere X and Lowell CA: The
multifaceted functions of neutrophils. Annu Rev Pathol Mech Dis.
9:181–218. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sagiv JY, Voels S and Granot Z: Isolation
and characterization of low- vs. High-density neutrophils in
cancer. Methods Mol Biol. 1458:179–193. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fridlender ZG and Albelda SM:
Tumor-associated neutrophils: Friend or foe? Carcinogenesis.
33:949–955. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Coffelt SB, Wellenstein MD and De Visser
KE: Neutrophils in cancer: Neutral no more. Nat Rev Cancer.
16:431–446. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gregory AD and Houghton AM:
Tumor-associated neutrophils: New targets for cancer therapy.
Cancer Res. 71:2411–2416. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Powell DR and Huttenlocher A: Neutrophils
in the tumor microenvironment. Trends Immunol. 37:41–52.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Brandau S, Moses K and Lang S: The kinship
of neutrophils and granulocytic myeloid-derived suppressor cells in
cancer: Cousins, siblings or twins? Semin Cancer Biol. 23:171–182.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nozawa H, Chiu C and Hanahan D:
Infiltrating neutrophils mediate the initial angiogenic switch in a
mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA.
103:12493–12498. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ueno H, Jones AM, Wilkinson KH, Jass JR
and Talbot IC: Histological categorisation of fibrotic cancer
stroma in advanced rectal cancer. Gut. 53:581–586. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Najafi M, Farhood B and Mortezaee K:
Contribution of regulatory T cells to cancer: A review. J Cell
Physiol. 234:7983–7993. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jakubowska K, Kisielewski W, Kańczuga-Koda
L, Koda M and Famulski W: Stromal and intraepithelial
tumor-infiltrating lymphocytes in colorectal carcinoma. Oncol Lett.
14:6421–6432. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagasaki T, Akiyoshi T, Fujimoto Y,
Konishi T, Nagayama S, Fukunaga Y and Ueno M: Prognostic impact of
neutrophil-to-lymphocyte ratio in patients with advanced low rectal
cancer treated with preoperative chemoradiotherapy. Dig Surg.
32:496–503. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Palin RP, Devine AT, Hicks G and Burke D:
Association of pretreatment neutrophil-lymphocyte ratio and outcome
in emergency colorectal cancer care. Ann R Coll Surg Engl.
100:308–315. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Artaç M, Uysal M, Karaağaç M, Korkmaz L,
Er Z, Güler T, Börüban MC and Bozcuk H: Prognostic impact of
neutrophil/lymphocyte ratio, platelet count, CRP, and albumin
levels in metastatic colorectal cancer patients treated with
FOLFIRI-bevacizumab. J Gastrointest Cancer. 48:176–180.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhou WW, Chu YP and An GY: Significant
difference of neutrophil-lymphocyte ratio between colorectal
cancer, adenomatous polyp and healthy people. Eur Rev Med Pharmacol
Sci. 21:5386–5391. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pedrazzani C, Mantovani G, Fernandes E,
Bagante F, Luca Salvagno G, Surci N, Campagnaro T, Ruzzenente A,
Danese E, Lippi G and Guglielmi A: Assessment of
neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and
platelet count as predictors of long-term outcome after R0
resection for colorectal cancer. Sci Rep. 7(1494)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen L, Yan Y, Zhu L, Cong X, Li S, Song
S, Song H and Xue Y: Systemic immune-inflammation index as a useful
prognostic indicator predicts survival in patients with advanced
gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag
Res. 9:849–867. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Özgehan G, Kahramanca Ş, Kaya IO, Bilgen
K, Bostanci H, Güzel H, Küçükpinar T and Kargici H:
Neutrophil-lymphocyte ratio as a predictive factor for tumor
staging in colorectal cancer. Turkish J Med Sci. 44:365–368.
2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Iseki Y, Shibutani M, Maeda K, Nagahara H,
Tamura T, Ohira G, Yamazoe S, Kimura K, Toyokawa T, Amano R, et al:
The impact of the preoperative peripheral lymphocyte count and
lymphocyte percentage in patients with colorectal cancer. Surg
Today. 47:743–754. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jankova L, Dent OF, Chan C, Chapuis P and
Clarke SJ: Preoperative neutrophil/lymphocyte ratio predicts
overall survival but does not predict recurrence or cancer-specific
survival after curative resection of node-positive colorectal
cancer. BMC Cancer. 13(442)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ying HQ, Deng QW, He BS, Pan YQ, Wang F,
Sun HL, Chen J, Liu X and Wang SK: The prognostic value of
preoperative NLR, d-NLR, PLR and LMR for predicting clinical
outcome in surgical colorectal cancer patients. Med Oncol.
31(305)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Balde AI, Fang S, He L, Cai Z, Han S, Wang
W, Li Z and Kang L: Propensity score analysis of recurrence for
neutrophil-to-lymphocyte ratio in colorectal cancer. J Surg Res.
219:244–252. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li H, Song J, Cao M, Wang G, Li L, Zhang
B, Li Y, Xu W and Zheng J: Preoperative neutrophil-to-lymphocyte
ratio is a more valuable prognostic factor than
platelet-to-lymphocyte ratio for nonmetastatic rectal cancer. Int
Immunopharmacol. 40:327–331. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ozdemir Y, Akin ML, Sucullu I, Balta AZ
and Yuce E: Pretreatment neutrophil/lymphocyte ratio as a
prognostic aid in colorectal cancer. Asian Pacific J Cancer Prev.
15:2647–2650. 2014.PubMed/NCBI View Article : Google Scholar
|
